On February 27, 2026 Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, reported its participation in the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

March 2, 2026
TD Cowen 46th Annual Health Care Conference
Boston, MA
9:10 a.m. EST – fireside chat

March 10, 2026
Leerink Global Healthcare Conference
Miami, FL
10:40 a.m. EDT – fireside chat

A simultaneous webcast of both events will be available on the Investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days.

(Press release, Nkarta, FEB 27, 2026, View Source [SID1234663128])

On February 27, 2026 Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, reported the launch of a private placement (the "Private Placement") of up to 20,000,000 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of up to $11,000,000. Each Unit will be comprised of one common share (each, a "Share") and one common share purchase warrant ("Warrants"). Each Warrant will entitle its holder to acquire an additional common share of the Company at a price of $0.65 per share for 24 months following the date of issuance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company has executed a binding term sheet with two arm’s length institutional investors (collectively, the "Investors") in connection with the Private Placement for aggregate gross proceeds of $6,000,000 (CAD) (the "Investors’ Proceeds"). In connection with the Private Placement, the Investors’ Proceeds and the Units will be deposited in escrow in advance of closing pursuant to an escrow agreement (the "Escrow Agreement"). Upon closing, the Units will be released from escrow and delivered to the Investors or as they may direct, and the Investors’ Proceeds will be released from escrow and deposited as credit support pursuant to an ISDA Credit Support Annex, and released to the Company in monthly cash tranches of $333,333 (CAD) over an 18-month period (the "Term"), pursuant to the terms and conditions of a sharing agreement (the "Sharing Agreement") to be dated and executed on the closing of the Private Placement. Settlements under the Sharing Agreement shall commence five months after closing.

Pursuant to the Sharing Agreement, Shares will be released in equal monthly installments of approximately 606,060 Shares over the 18-month Term, with each release contingent upon the corresponding cash payment being delivered to the Company. The Sharing Agreement shall provide that the Company’s economic interest will be determined in 18 monthly settlement tranches as measured against a benchmark price of $0.7332 (CAD) per Share (the "Benchmark Price"). If, at the time of settlement, the settlement price (determined monthly based on a 20-day volume-weighted average trading price of the Company’s shares on the CSE) exceeds the Benchmark Price, the Company shall receive more than 100% of the monthly settlement due, on a pro rata basis, with no upper limit on additional proceeds. If the settlement price is below the Benchmark Price, the Company will receive less than 100% of the monthly settlement due, on a pro rata basis. In no event will a decline in the settlement price result in an increase in the number of Shares being issued to the Investors. As a result, the Company may ultimately receive more or materially less than the original proceeds of $6,000,000. The final amount received will depend on the Company’s future share price, which is subject to market fluctuations and may vary over time. Accordingly, there is no assurance as to the total amount the Company will receive under the Sharing Agreement.

All 10,909,091 Warrants to be issued shall be exercisable at an exercise price of $0.65 (CAD) per Share for a period of 24 months following the date of issuance. The Warrants will include an equity blocker provision that prohibits the holder from exercising any portion of the Warrants if such exercise would result in the holder owning more than 9.99% of the Company’s outstanding Shares.

The Investors will receive a corporate finance fee of $360,000 (CAD) in connection with the Sharing Agreement, payable in cash or via the issuance of 654,546 Units at the Private Placement price, at the election of the Company (the "Fee").

The Company has agreed to pay a non-refundable deposit of $65,000 (CAD)
(the "Deposit") upon receipt of approval from the CSE in connection with the Private Placement. The Deposit shall be satisfied by the issuance of 118,182 Units at the Private Placement price.

Defence intends to use the proceeds from the Private Placement to advance its Antibody Drug Conjugate ("ADC") and Radiopharmaceutical programs, to develop partnerships and for working capital purposes. The Company may pay a finder’s fee in connection with the offering to eligible arm’s-length finders in accordance with the policies of the Canadian Securities Exchanges.

Pursuant to applicable Canadian securities laws and in accordance with the Exchange policies, all securities issued under this Private Placement will be subject to applicable resale restrictions under applicable securities laws. The closing of the Private Placement is expected on or about March 6, 2026, subject to the approval of the CSE.

The Units described herein have not been, and will not be, registered under the U.S. Securities Act or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions there from. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

(Press release, Defence Therapeutics, FEB 27, 2026, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-announces-private-placement-of-units-for-proceeds-of-up-to-11-million [SID1234663221])

On February 27, 2026 Novartis AG (NYSE: NVS) reported that it has successfully completed its acquisition of Avidity Biosciences, Inc. ("Avidity"). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Avidity’s breakthrough science combined with Novartis capabilities will help reimagine what’s possible for people with devastating genetic neuromuscular diseases," said Vas Narasimhan, CEO of Novartis. "Avidity’s muscle-directed AOC platform and late-stage programs advance our RNA therapeutics and have the potential to deliver first-in-disease therapies. With the close of the acquisition, we’re excited to welcome Avidity to Novartis and accelerate this next generation of medicines."

Novartis completed the acquisition of Avidity through the merger of its indirect wholly owned subsidiary, Ajax Acquisition Sub, Inc., with and into Avidity. As a result of the merger, holders of Avidity common stock became entitled to receive USD 72.00 per share in cash, valuing the company at approximately USD 12bn on a fully diluted basis and representing an enterprise value of approximately USD 11bn. Avidity’s shares of common stock have also ceased trading on the Nasdaq Stock Market LLC. The transaction was originally announced on Oct. 26, 2025.

(Press release, Novartis, FEB 27, 2026, View Source [SID1234663129])

On February 27, 2026 OPKO Health, Inc. (Nasdaq: OPK) reported that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in scheduling a meeting with OPKO management should contact their Jefferies representative.

(Press release, Opko Health, FEB 27, 2026, View Source [SID1234663130])

On February 27, 2026 PharmaMar Group (MSE:PHM) reported to have closed the 2025 financial year with a 27% increase in total revenues, reaching €221.4 million. Recurring revenues, resulting from the sum of net sales plus royalties received from its partners, increased by 12% compared to the previous year, reaching €143.5 million. Non-recurring revenues increased by 66% compared to the end of December 2024, reaching €77.9 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Net sales in oncology closed the year with a growth of 20%, reaching €79.7 million. This growth was driven by a 31% increase in revenue from Zepzelca (lurbinectedin) in Europe to €37.5 million. This section saw growth in revenue both from the compassionate use program, which totaled €26.2 million (+18%) and sales in Switzerland, which reached €11.3 million in 2025 (+77%).

Sales of raw materials to our partners of both lurbinectedin and Yondelis (trabectedin) grew by 37% to €27.5 million. Commercial sales of trabectedin in Europe were €14.7 million, compared to €18.0 million in the same period last year.

As of December 31st, 2025, oncology royalty income increased by 4% to €63.8 million compared to the same period last year.

Royalties received from our partners for sales of lurbinectedin, mainly from our partner Jazz Pharmaceuticals in the US, reached €51.6 million compared to €56.1 million in December 2024. In this regard, it is important to note that last October, lurbinectedin in combination with atezolizumab (Tecentriq) was approved by the US Food and Drug Administration (FDA) to expand its use to first-line maintenance treatment in extensive-stage small cell lung cancer. As a result, lurbinectedin revenues in the fourth quarter in the US were approximately $90 million, making it the highest quarterly sales since the launch of lurbinectedin in the US and representing a 15% year-on-year growth compared to the fourth quarter of 2024. This sales growth was primarily driven by the initial demand for first-line maintenance treatment.

It is also worth noting the significant increase in royalties received from sales of trabectedin in the US, which more than doubled the €4.5 million recorded in 2024 to achieve €11.6 million. These sales have been boosted since its inclusion in the NCCN treatment guidelines in that country for first-line use following positive results from a Phase III trial in combination with doxorubicin.

As for non-recurring income from licensing agreements, at the end of 2025, this increased by 67% to €77.8 million. Of this total amount, €42.5 million ($50 million) corresponds to the milestone payment achieved for FDA’s full approval of lurbinectedin, €21.3 million relates to the upfront payment for the lurbinectedin licensing agreement in Japan and another €8.6 million ($10 million) corresponds to the payment of a commercial milestone established in the trabectedin licensing agreement in the US. In addition, €4.0 million correspond to the deferred revenue portion of the 2019 agreement with Jazz Pharmaceuticals, another €1.3 million correspond to revenue from several minor agreements.

As of December 31st, 2025, PharmaMar Group’s investment in R&D stood at €95.2 million, compared to €103.5 million as of December 31st, 2024. This investment represents 43% of PharmaMar Group’s total revenue.

Of the total investment in R&D during the year, the oncology segment reached €92.4 million, compared to €94.4 million in December 2024. This difference is due to the completion of patient recruitment for the Phase III LAGOON trial for second-line treatment of small cell lung cancer, with results expected in the third quarter of 2026. Meanwhile, the Phase III SaLuDo clinical trial with lurbinectedin in the first-line treatment of metastatic leiomyosarcoma continues to progress, with recruitment expected to be completed in the middle of this year with data expected in the 1st half of 2027.

In addition, the Company continues to invest in the clinical development of other molecules at earlier stages. Phase I clinical trials are underway with PM534 and PM54 for the treatment of solid tumors. In December 2025, the FDA approved the start of a Phase I/II trial with PM54 in combination with immunotherapy in solid tumors.

The significant growth in revenues enabled PharmaMar Group to achieve EBITDA of €68.1 million at December 31st, 2025, compared with €13.0 million in 2024.

As a result, the Company will increase its net profit by 187% to €75.0 million.

As of December 31st, 2025, PharmaMar Group’s cash and cash equivalents balance increased by €10.8 million to €167.8 million. Total financial debt was reduced by €1.3 million to €46.6 million. As a result, the net cash position at year-end stood at €121.2 million.

The Board of Directors of Pharma Mar, S.A. will propose to the General Shareholders’ Meeting the distribution of a dividend of €1.00 per outstanding share that will be charged to unrestricted reserves (share premium), up to a maximum amount of 18,000,000.00 Euros.

PharmaMar is organizing a conference call with analysts and investors on February 27th, 2026, at 1:30 p.m. (CET). To join the conference call, please register at this link to receive the access numbers and a personalized PIN.

To access without prior registration, use the following numbers: +34 919 01 16 44 (Spain), +1 646 233 4753 (US or Canada), or +44 20 3936 2999 (UK). Conference number: 636061.

(Press release, PharmaMar, FEB 27, 2026, View Source [SID1234663131])